Indaptus Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Indaptus Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 622% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 63% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Indaptus Therapeutics, Inc. made a loss over the last year. Indaptus Therapeutics, Inc. owes $0.05 for every $1 it owns. Indaptus Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossIndaptus Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
35.03The share price is 35.03 times Indaptus Therapeutics, Inc.'s book value per share, higher than 97% of Healthcare companies in United States.
Market cap
$398 MThe total market value of all of Indaptus Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$11 MWhat Indaptus Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.09Net worth divided by the number of shares. The share price of $2.99 is 35.0 times this, which is the P/B above.
Return on equity (ROE)
-318.0%Indaptus Therapeutics, Inc. lost 318.0% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
Owes vs Owns
0.05×Indaptus Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Dividend yield
NoneIndaptus Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossIndaptus Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashIndaptus Therapeutics, Inc. held $9 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Indaptus Therapeutics, Inc.: $398 M ÷ $11 M (30 Jun 2026) = 35.0.
What is Indaptus Therapeutics, Inc.'s return on equity?
Indaptus Therapeutics, Inc. lost 318.0% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
How much does Indaptus Therapeutics, Inc. owe compared with what it owns?
Indaptus Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Does Indaptus Therapeutics, Inc. pay a dividend?
No. Indaptus Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.